11,039 Shares in AstraZeneca PLC $AZN Purchased by Oliver Lagore Vanvalin Investment Group

Key Points

• Oliver Lagore Vanvalin Investment Group acquired 11,039 shares of AstraZeneca PLC, valued at approximately $811,000, in the second quarter of the year.
• A number of institutional investors, including Goldman Sachs and American Century Companies, have significantly increased their holdings in AstraZeneca, with Goldman Sachs raising its position by 30.9%.
• AstraZeneca reported a quarterly revenue of $14.46 billion, exceeding analyst estimates, and announced a semi-annual dividend of $0.505 per share.

Oliver Lagore Vanvalin Investment Group bought a new stake in AstraZeneca PLC (NASDAQ:AZN - Free Report) in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 11,039 shares of the company's stock, valued at approximately $811,000.

Other institutional investors have also recently bought and sold shares of the company. Brighton Jones LLC lifted its position in AstraZeneca by 93.2% during the fourth quarter. Brighton Jones LLC now owns 5,782 shares of the company's stock valued at $379,000 after buying an additional 2,789 shares in the last quarter. American Assets Inc. acquired a new stake in AstraZeneca in the fourth quarter valued at $426,000. Toronto Dominion Bank increased its stake in AstraZeneca by 51.0% during the fourth quarter. Toronto Dominion Bank now owns 27,080 shares of the company's stock valued at $1,774,000 after purchasing an additional 9,151 shares during the last quarter. Tidal Investments LLC increased its stake in AstraZeneca by 9.6% during the fourth quarter. Tidal Investments LLC now owns 7,284 shares of the company's stock valued at $477,000 after purchasing an additional 635 shares during the last quarter. Finally, Two Sigma Advisers LP bought a new stake in AstraZeneca during the fourth quarter valued at $5,641,000. 20.35% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Separately, Berenberg Bank set a $97.00 target price on shares of AstraZeneca in a research report on Wednesday, July 9th. Three equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, AstraZeneca has an average rating of "Moderate Buy" and an average target price of $86.00.

AstraZeneca Stock Performance

AZN stock traded down $1.33 during midday trading on Tuesday, hitting $76.18. 1,875,807 shares of the company traded hands, compared to its average volume of 5,077,903. AstraZeneca PLC has a twelve month low of $61.24 and a twelve month high of $82.41. The company has a quick ratio of 0.67, a current ratio of 0.86 and a debt-to-equity ratio of 0.55. The business has a 50 day simple moving average of $76.73 and a 200-day simple moving average of $72.94. The stock has a market capitalization of $236.25 billion, a price-to-earnings ratio of 28.63, a price-to-earnings-growth ratio of 1.40 and a beta of 0.37.

AstraZeneca (NASDAQ:AZN - Get Free Report) last posted its quarterly earnings data on Tuesday, July 29th. The company reported $1.09 earnings per share for the quarter, meeting the consensus estimate of $1.09. The company had revenue of $14.46 billion during the quarter, compared to analysts' expectations of $14.08 billion. AstraZeneca had a return on equity of 32.84% and a net margin of 14.68%.AstraZeneca's revenue for the quarter was up 16.1% compared to the same quarter last year. During the same period in the prior year, the business earned $1.24 earnings per share. As a group, equities research analysts predict that AstraZeneca PLC will post 4.51 earnings per share for the current year.

AstraZeneca Cuts Dividend

The business also recently disclosed a semi-annual dividend, which was paid on Monday, September 8th. Shareholders of record on Friday, August 8th were issued a dividend of $0.505 per share. The ex-dividend date of this dividend was Friday, August 8th. This represents a dividend yield of 200.0%. AstraZeneca's dividend payout ratio (DPR) is presently 37.97%.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.